| 1 |
34519068 | Evaluation of the drug-drug interaction potential of treosulfan using a physiologically-based pharmacokinetic modelling approach. | 2022 Feb |
1 |
| 2 |
34903590 | Intersystem Extrapolation Factors Are Substrate-Dependent for CYP3A4: Impact on Cytochrome P450 Reaction Phenotyping. | 2022 Mar |
1 |
| 3 |
35184709 | Inhibition of Cytochrome P450 Enzyme and Drug-Drug Interaction Potential of Acid Reducing Agents Used in Management of CDK Inhibitors for Breast Cancer Chemotherapy. | 2022 |
3 |
| 4 |
35399214 | Characterization of furathiocarb metabolism in in-vitro human liver microsomes and recombinant cytochrome P450 enzymes. | 2022 |
1 |
| 5 |
33064292 | Physiologically Based Pharmacokinetic Modeling Approach to Identify the Drug-Drug Interaction Mechanism of Nifedipine and a Proton Pump Inhibitor, Omeprazole. | 2021 Jan |
4 |
| 6 |
33191904 | Relative contributions of metabolic enzymes to systemic elimination can be estimated from clinical DDI studies: Validation using an in silico approach. | 2021 Mar |
1 |
| 7 |
33355212 | Evaluation of Tissue Stem Cell-Derived Human Intestinal Organoids, a Physiologically Relevant Model to Evaluate Cytochrome P450 Induction in Gut. | 2021 Mar |
1 |
| 8 |
34345857 | Primary hepatocytes isolated from human and porcine donors display similar patterns of cytochrome p450 expression following exposure to prototypical activators of AhR, CAR and PXR. | 2021 |
1 |
| 9 |
32276526 | Cytochrome P450 (CYP450) Interactions Involving Atypical Antipsychotics are Common in Community-Dwelling Older Adults Treated for Behavioral and Psychological Symptoms of Dementia. | 2020 Apr 8 |
1 |
| 10 |
32350061 | Enrichment-free High-throughput Liquid Chromatography-Multiple-Reaction Monitoring Quantification of Cytochrome P450 Proteins in Plated Human Hepatocytes Direct from 96-Well Plates Enables Routine Protein Induction Measurements. | 2020 Jul |
1 |
| 11 |
32558923 | Effect of High-Dose Esomeprazole on CYP1A2, CYP2C19, and CYP3A4 Activities in Humans: Evidence for Substantial and Long-lasting Inhibition of CYP2C19. | 2020 Dec |
2 |
| 12 |
30992242 | Influences of cytochrome b5 expression and its genetic variant on the activity of CYP2C9, CYP2C19 and CYP3A4. | 2019 Jun |
1 |
| 13 |
31236938 | Altered cytochrome 2E1 and 3A P450-dependent drug metabolism in advanced ovarian cancer correlates to tumour-associated inflammation. | 2019 Sep |
1 |
| 14 |
31807051 | Antihypertensive Effect Of Amlodipine In Co-Administration With Omeprazole In Patients With Hypertension And Acid-Related Disorders: Cytochrome P450-Associated Aspects. | 2019 |
1 |
| 15 |
29063606 | Harnessing Meta-analysis to Refine an Oncology Patient Population for Physiology-Based Pharmacokinetic Modeling of Drugs. | 2018 Feb |
1 |
| 16 |
29357810 | Cytochrome P450 1A2 Messenger RNA is a More Reliable Marker than Cytochrome P450 1A2 Activity, Phenacetin O-Deethylation, for Assessment of Induction Potential of Drug-Metabolizing Enzymes Using HepaRG Cells. | 2018 |
2 |
| 17 |
29377228 | Developmental pharmacogenetics of CYP2C19 in neonates and young infants: omeprazole as a probe drug. | 2018 May |
1 |
| 18 |
29733119 | Correspondence between the CYP2C19 and CYP3A4 genotypes with the inferred metabolizer phenotype by omeprazole administration in Mexican healthy children. | 2018 Oct |
2 |
| 19 |
29741901 | Stereoselective Metabolism of Omeprazole by Cytochrome P450 2C19 and 3A4: Mechanistic Insights from DFT Study. | 2018 Jun 7 |
2 |
| 20 |
29950882 | CYP3A and CYP2C19 activity in urine in relation to CYP3A4, CYP3A5, and CYP2C19 polymorphisms in Russian peptic ulcer patients taking omeprazole. | 2018 |
3 |
| 21 |
30347615 | Optimized protocol for induction of cytochrome P450 enzymes 1A2 and 3A4 in human primary-like hepatocyte cell strain HepaFH3 to study in vitro toxicology. | 2018 |
1 |
| 22 |
25719441 | Effect of Omeprazole on the Pharmacokinetics of Rosuvastatin in Healthy Male Volunteers. | 2016 Nov/Dec |
1 |
| 23 |
26724677 | Functional polymer-dependent 3D culture accelerates the differentiation of HepaRG cells into mature hepatocytes. | 2016 Sep |
1 |
| 24 |
27216294 | A short-term high fat diet increases exposure to midazolam and omeprazole in healthy subjects. | 2016 Jul |
1 |
| 25 |
27764027 | Quantitative Method for Simultaneous Analysis of a 5-Probe Cocktail for Cytochrome P450 Enzymes. | 2016 Dec |
1 |
| 26 |
24390778 | Pharmacokinetics of omeprazole and its metabolites in three phases of menstrual cycle. | 2015 Mar |
2 |
| 27 |
25600204 | Human HepaRG Cells can be Cultured in Hanging-drop Plates for Cytochrome P450 Induction and Function Assays. | 2015 |
1 |
| 28 |
26614990 | In vitro inhibitory effects of plumbagin, the promising antimalarial candidate, on human cytochrome P450 enzymes. | 2015 Nov |
1 |
| 29 |
23629159 | Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype dependent. | 2014 Apr |
1 |
| 30 |
24016712 | Human variation and CYP enzyme contribution in benfuracarb metabolism in human in vitro hepatic models. | 2014 Jan 13 |
1 |
| 31 |
24550106 | Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. | 2014 Apr |
1 |
| 32 |
24553381 | Evaluation of 23 lots of commercially available cryopreserved hepatocytes for induction assays of human cytochromes P450. | 2014 May |
1 |
| 33 |
25141173 | Omeprazole and lansoprazole enantiomers induce CYP3A4 in human hepatocytes and cell lines via glucocorticoid receptor and pregnane X receptor axis. | 2014 |
5 |
| 34 |
23620487 | Inhibition of CYP2C19 and CYP3A4 by omeprazole metabolites and their contribution to drug-drug interactions. | 2013 Jul |
4 |
| 35 |
23857299 | In vitro inhibition of methadone and oxycodone cytochrome P450-dependent metabolism: reversible inhibition by H2-receptor agonists and proton-pump inhibitors. | 2013 Oct |
1 |
| 36 |
22313038 | Different effects of proton pump inhibitors and famotidine on the clopidogrel metabolic activation by recombinant CYP2B6, CYP2C19 and CYP3A4. | 2012 Jul |
2 |
| 37 |
22318618 | Induction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteers. | 2012 Mar |
1 |
| 38 |
21499896 | Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer. | 2011 Dec |
1 |
| 39 |
21832258 | Luciferin IPA-based higher throughput human hepatocyte screening assays for CYP3A4 inhibition and induction. | 2011 Sep |
1 |
| 40 |
20019244 | Stable expression, activity, and inducibility of cytochromes P450 in differentiated HepaRG cells. | 2010 Mar |
1 |
| 41 |
20307514 | Metabolism of carbosulfan II. Human interindividual variability in its in vitro hepatic biotransformation and the identification of the cytochrome P450 isoforms involved. | 2010 May 14 |
1 |
| 42 |
20350051 | Effect of glycyrrhizin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypes. | 2010 Jun |
1 |
| 43 |
24688155 | Pharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers: a prospective pilot study. | 2010 Dec |
1 |
| 44 |
19451401 | Evaluation of luciferin-isopropyl acetal as a CYP3A4 substrate for human hepatocytes: effects of organic solvents, cytochrome P450 (P450) inhibitors, and P450 inducers. | 2009 Aug |
1 |
| 45 |
18214455 | Effects of the CYP3A5 genotype on omeprazole sulfoxidation in CYP2C19 PMs. | 2008 Jun |
1 |
| 46 |
18581106 | Investigation of the in vivo activity of CYP3A in Brazilian volunteers: comparison of midazolam and omeprazole as drug markers. | 2008 Sep |
1 |
| 47 |
17203292 | Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations. | 2007 Feb |
1 |
| 48 |
16109480 | Role of CYP3A4 in the regulation of the aryl hydrocarbon receptor by omeprazole sulphide. | 2006 May |
1 |
| 49 |
16415114 | In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism. | 2006 Apr |
2 |
| 50 |
16490811 | Use of omeprazole as a CYP3A probe drug: effect of sex and menstrual cycle phase on CYP3A activity in healthy Caucasian adults. | 2006 Mar |
1 |